Best-in-class solutions with an open architecture approach

The biotherapeutic market has been rapidly adopting single-use technologies to reduce risk and improve operational efficiencies. Single-use technologies have been proven to be robust and scalable from lab/scale-up to cGMP production applications including, single-use bioprocessing equipment, flexible containment, and rigid containment product portfolios.

Libbs discusses how their partnership with Thermo Fisher Scientific, aids in their mission to help people to achieve a full life. They pride themselves to have built the business with a mixture of innovation and vision.